WallStreetZenWallStreetZen

NASDAQ: RXRX
Recursion Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Recursion Pharmaceuticals earnings were -$574.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest RXRX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$202.5M, up 13.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RXRX reported annual earnings of -$463.7M, with 41.3% growth.

RXRX earnings history

Current Revenue
$59.8M
Current Earnings
-$574.8M
Current Profit Margin
-961.3%

RXRX Return on Equity

Current Company
-74.7%
Current Industry
-60.5%
Current Market
28.2%
RXRX's Return on Equity (-74.7%)... subscribe to Premium to read more.
High Return on Equity Performance

RXRX undefined

Current Company
-54%
Current Industry
-2.3%
RXRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RXRX announces earnings.

RXRX undefined

Current Company
-49.45%
Current Industry
6.2%
RXRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RXRX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RXRX-$506.56M-$574.78MN/A-$1.81
ARQT-$100.65M-$129.72MN/A-$1.03
IDYA-$303.20M-$307.08MN/A-$3.65
IRON-$114.00M-$116.49MN/A-$3.92
BEAM-$355.61M-$387.34MN/A-$4.61
View Top Biotech Stocks

Recursion Pharmaceuticals Earnings Reports & History FAQ

What were Recursion Pharmaceuticals's earnings last quarter?

On RXRX's earnings call on Invalid Date, Recursion Pharmaceuticals (NASDAQ: RXRX) reported Q1 2025 earnings per share (EPS) of -$0.50, up 28.21% year over year. Total RXRX earnings for the quarter were -$202.49 million. In the same quarter last year, Recursion Pharmaceuticals's earnings per share (EPS) was -$0.39.

If you're new to stock investing, here's how to buy Recursion Pharmaceuticals stock.

Is Recursion Pharmaceuticals profitable or losing money?

As of the last Recursion Pharmaceuticals earnings report, Recursion Pharmaceuticals is currently losing money. Recursion Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$574.78 million, a 62.31% increase year over year.

What was RXRX's earnings growth in the past year?

As of Recursion Pharmaceuticals's earnings date in Invalid Date, Recursion Pharmaceuticals's earnings has grown year over year. RXRX earnings in the past year totalled -$574.78 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.